v**********m
发帖数: 5516 | 1 Cash/share (Dec 30, 2010)
$1.13/share ($150,669,000/133,680,000)
-----------------------------------------------------------
刚增发过，到明年没问题。
Arena Pharmaceuticals Announces $35.5 Million Financing
- Arena to Use Approximately $17.7 Million of Proceeds to Prepay Outstanding
Debt -
SAN DIEGO, March 29, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (
Nasdaq: ARNA) announced today that it has agreed to sell 12,150,000 shares
of its common stock, at a price of $1.46 per share, and 12,150 shares of its
Series C Convertible Preferred Stock, at a price of $1,460 per share, in a
registered direct public offering to entities affiliated with Deerfield
Management, a healthcare investment organization. The preferred stock is
convertible into an aggregate of 12,150,000 shares of Arena common stock.
Arena expects to receive gross proceeds of approximately $35.5 million. The
closing of the offering is expected to take place on or about March 31, 2011
.
--------------------------------------------------------------------
2011年，他们expect to resubmit the lorcaserin NDA by the end of 2011。
December 22, 2010
Arena and Eisai Complete End-of-Review Meeting with FDA for Lorcaserin New
Drug Application
-- Meeting Provides Additional Clarity on Next Steps Toward Approval --
-- Arena to Host Conference Call and Webcast at 8:30 a.m. Eastern Time Today
--
SAN DIEGO and WOODCLIFF LAKE, N.J., Dec. 22, 2010 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (Nasdaq: ARNA) and Eisai Inc. announced today the
completion of an end-of-review meeting with the US Food and Drug
Administration (FDA) for the lorcaserin New Drug Application (NDA).
"The meeting discussions reinforce our position that we have a path forward
to seek FDA approval of lorcaserin," said Jack Lief, Arena's President and
Chief Executive Officer. "Based on guidance we have received from the agency
, we are executing several activities and expect to resubmit the lorcaserin
NDA by the end of 2011. As we continue discussions with the FDA to refine
elements of our plan, we may identify ways to shorten this timeline. We will
provide more details about our plan on the conference call and webcast this
morning."
Arena submitted an NDA for lorcaserin to the FDA in December 2009, and the
FDA issued a Complete Response Letter (CRL) in October 2010. In the CRL, the
FDA outlined non-clinical and clinical reasons for its decision and
provided recommendations relating to addressing such issues. The end-of-
review meeting with the FDA included a discussion of the FDA's position on
issues identified in the CRL and Arena's plan to respond.
-------------------------------------------------
Any negative comments are welcome. -by var | w******i
发帖数: 1476 | 2 唏嘘一下, 年头炒过, 2块多卖的, 后来没注意竟然掉成这样了 | v**********m
发帖数: 5516 | 3 韭菜自有后来人。
此一时，彼一时。
【在 w******i 的大作中提到】
: 唏嘘一下, 年头炒过, 2块多卖的, 后来没注意竟然掉成这样了
| w******i
发帖数: 1476 | 4 nod nod
will research on it
waiting for Daniu's opinions.
【在 v**********m 的大作中提到】
: 韭菜自有后来人。
: 此一时，彼一时。
| v**********m
发帖数: 5516 | | w*******d
发帖数: 3714 | | b*****h
发帖数: 783 | 7 远没有解决。。
【在 w*******d 的大作中提到】
: 他们的老鼠问题解决了么。。。
| v**********m
发帖数: 5516 | 8 这个问题无解。大家玩的都是pre events。
【在 w*******d 的大作中提到】
: 他们的老鼠问题解决了么。。。
|
|
